Clinical trial
Efficacy and Safety Study of Cilostazol to Prevent Reoccurrence of Stroke
NCT00202020 · Otsuka Beijing Research Institute, Industry · Completed
Key facts
| NCT number | NCT00202020 |
|---|---|
| Title | Efficacy and Safety Study of Cilostazol to Prevent Reoccurrence of Stroke |
| Official title | Cilostazol Stroke Prevention Study-a Randomized, Double Blind, Double Dummy, Parallel Comparative, Multicenter Clinical Trial |
| Lead sponsor | Otsuka Beijing Research Institute, Industry |
| Collaborators | Zhejiang Otsuka Pharmaceutical Co., Ltd. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cerebral Infarction |
| Intervention type | Drug |
| Interventions | Cilostazol 200mg/day Oral, Aspirin 100mg/day Oral |
| Enrollment | 720 |
| Start date | May 1, 2004 |
| Completion | Jan 1, 2006 |
| First posted | Sep 20, 2005 |
| Last update posted | Mar 16, 2006 |
| Countries | China |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: